M. Abdul-ghani, L. Norton, and R. Defronzo, Role of Sodium

L. Baggio and D. Drucker, Biology of Incretins: GLP-1 and GIP, Gastroenterology, vol.132, issue.6, pp.2131-2157, 2007.
DOI : 10.1053/j.gastro.2007.03.054

R. Bergenstal, C. Wysham, L. Macconell, J. Malloy, B. Walsh et al., Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial, The Lancet, vol.376, issue.9739, pp.431-439, 2010.
DOI : 10.1016/S0140-6736(10)60590-9

T. Blevins, J. Pullman, J. Malloy, . P. Yan, K. Taylor et al., DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.5, pp.1301-1310, 2011.
DOI : 10.1210/jc.2010-2081

L. Inhibiteurs-des-alpha-glucosidases, La Revue de Médecine Interne, pp.379-383, 1999.

F. Bosquet and A. Hartemann-heurtier, Insulinothérapie dans le Diabète de Type II, pp.55-65, 2004.

D. Bradley, R. Kulstad, and D. Schoeller, Exenatide and weight loss, Nutrition, vol.26, issue.3, pp.243-249, 2010.
DOI : 10.1016/j.nut.2009.07.008

B. Okopien and . Exenatide, Agonist) Expresses Anti-Inflammatory Properties in Cultured Human Monocytes / Macrophages in a Protein Kinase A and B / Akt Manner, Pharmacological Reports, vol.68, issue.2, pp.329-337, 2016.

M. Boardman, M. Fineman, L. Porter, and G. Schemthaner, Exenatide Once Weekly Versus Liraglutide Once Daily in Patients With Type 2 Diabetes (DURATION-6) : a Randomised, Open-Label Study. The Lancet, pp.117-124, 2013.

J. Buteau, Incretins : a New Approch ; GLP-1 Receptor Singnaling : Effects on Pancreatic ?- Cell Proliferation and Survival. Diabetes and Metabolisme, pp.73-77, 2008.

B. Callaghan, H. Cheng, C. Stables, A. Smith, and E. Feldman, Diabetic neuropathy: clinical manifestations and current treatments, The Lancet Neurology, vol.11, issue.6, pp.521-534, 2012.
DOI : 10.1016/S1474-4422(12)70065-0

D. Young, M. , M. Conell, L. Sarin, V. Trautmann et al., Encapsulation of Exenatide in Poly-(D,L-lactide-co-glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes, Diabetes Technology and Therapeutics, vol.13, issue.11, pp.1145-1154, 2013.

D. Drucker, J. Buse, K. Taylor, D. Kendall, M. Trautmann et al., Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study, The Lancet, vol.372, issue.9645, pp.1240-1250, 2008.
DOI : 10.1016/S0140-6736(08)61206-4

G. Strauch, Activité Physique et Diabète de

B. Dussol, . Equilibre-potassique, . Hypokaliémie, and . Hyperkaliémie, ??quilibre potassique, hypokali??mie et hyperkali??mie, N??phrologie & Th??rapeutique, vol.6, issue.3, pp.180-199, 2010.
DOI : 10.1016/j.nephro.2010.03.004

J. Eng, W. Kleinman, L. Singh, G. Singh, and J. Raufman, Isolation and Characterization of Exendin-4, an Exendin-3 Analogue from Heloderma Suspectum Venom, The Journal of Biological Chemestry, vol.267, issue.11, pp.7402-7405, 1992.

E. Ferrannini, S. Ramos, A. Salsali, W. Tang, and J. List, Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial, Diabetes Care, vol.33, issue.10, pp.2217-2224, 2010.
DOI : 10.2337/dc10-0612

C. Foote, V. Perkovic, and B. Neal, Effects of SGLT2 Inhibitors on Cardiovascular Outcomes. Diabetes and Vascular Disease Research, pp.117-123, 2012.

B. Furman, The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent, Toxicon, vol.59, issue.4, pp.464-471, 2012.
DOI : 10.1016/j.toxicon.2010.12.016

J. Gautier, S. Choukem, and . Incrétines, Les incr??tines, Nutrition Clinique et M??tabolisme, vol.22, issue.2, pp.59-65, 2008.
DOI : 10.1016/j.nupar.2008.04.009

R. Goldenberg, Z. Punthakee, and Z. Définition, D??finition, classification et diagnostic du diab??te, du pr??diab??te et du syndrome m??tabolique, Classification et Diagnostic du Diabète, du Prédiabète et du Syndrome Métabolique, pp.369-372
DOI : 10.1016/j.jcjd.2013.07.031

J. Girard, Les Actions Physiologiques de l'Insuline. Médecine des Maladies Métaboliques, pp.124-129, 2008.

R. G. George and S. Joseph, A Review of Newer Treatment Approaches for Type-2 Diabetes

S. Halimi, Cancers du pancr??as et s??curit?? des incr??tines : ??tat des lieux en 2014, Médecine des Maladie Métaboliques, pp.380-391, 2014.
DOI : 10.1016/S1957-2557(14)70835-1

H. L. Autorité-de-santé and . Bydureon, Avis de la Commission de Transparence, 2014.

H. L. Autorité-de-santé and . Glucophage, Avis de la Comission de Transparence, 2015.

H. L. Autorité-de-santé and . Stagid, Avis de la Commission de Transparence, 2012.

H. L. Autorité-de-santé and . Victoza, Avis de la Commission de Transparence, Décembre, 2009.

H. Autorité and D. Santé, Actualisation du Référentiel de Pratiques de l'Examen Périodique de Santé, Octobre 2014b, Prévention et Dépistage du Diabète de Type 2 et des Maladies Liées au Diabète

M. Houchin, S. Neuenswander, and E. Topp, Effect of excipients on PLGA film degradation and the stability of an incorporated peptide, Journal of Controlled Release, vol.117, issue.3, pp.413-420, 2007.
DOI : 10.1016/j.jconrel.2006.11.023

S. Johnston, H. Nguyen, K. Cappell, J. Nelson, B. Chu et al., Adherence to Liraglutide once daily or exenatide once weekly Over A 12-Month period among Commercially Insured Patients With Type 2 diabetes Mellitus: A retrospective observational study, Value in Health, vol.18, issue.3, 2015.
DOI : 10.1016/j.jval.2015.03.374

S. Kasichayanula, X. Liu, M. Benito, M. Yao, M. Pfister et al., The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus, British Journal of Clinical Pharmacology, vol.42, issue.Suppl. 1, pp.432-444, 2013.
DOI : 10.1111/bcp.12056

S. Lesven, J. Gautier, and R. Maréchaud, Treatment of Diabètes : New Clinical Studies and Effects of GLP-1 on Macrovascular Complications. Annales d'Endocrinologie, pp.505-510, 2010.

R. Liang, X. Li, Y. Shi, A. Wang, K. Sun et al., Effect of water on exenatide acylation in poly(lactide-co-glycolide) microspheres, International Journal of Pharmaceutics, vol.454, issue.1, pp.344-353, 2013.
DOI : 10.1016/j.ijpharm.2013.07.012

C. Magnan and A. Ktorza, Production et s??cr??tion de l'insuline par la cellule ?? pancr??atique, EMC - Endocrinologie, vol.2, issue.4
DOI : 10.1016/j.emcend.2005.07.001

L. Mandereau-bruno, P. Denis, A. Fagot-campagna, and S. Fosseedorh, Prévalence du Diabète Traité Pharmacologiquement et Disparités Territoriales en France en 2012 Bulletin Epidémiologique Hebdomadaire, Numéro 30-31, Novembre 2014, Pages 493-499 Diabète : des disparités sociales et territoriales importantes, Bull Epidémiol Hebd, pp.30-3149230, 2014.

M. Moon, P. S. Kim, D. Cho, E. Hwang, J. Vaudry et al., Structural and molecular conservation of glucagon-like peptide-1 and its receptor confers selective ligandreceptor interaction, Frontiers in Endocrinology, vol.141, issue.3, 2012.

S. Mudaliar and R. Henry, Effects of Incretin Hormones on ??-Cell Mass and Function, Body Weight, and Hepatic and Myocardial Function, The American Journal of Medicine, vol.123, issue.3, pp.19-27, 2010.
DOI : 10.1016/j.amjmed.2009.12.006

L. Nielsen, A. Young, and D. Parkes, Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes, Regulatory Peptides, vol.117, issue.2, pp.77-88, 2004.
DOI : 10.1016/j.regpep.2003.10.028

S. Nisly, D. Kolanczyk, and A. Walton, Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes, American Journal of Health-System Pharmacy, vol.70, issue.4, pp.311-319, 2013.
DOI : 10.2146/ajhp110514

P. Norwood, J. Liutkus, H. Haber, E. Pintilei, M. Boardman et al., Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With a Thiazolidinedione Alone or in Combination With Metformin for 2 Years, Clinical Therapeutics, vol.34, issue.10, 2012.
DOI : 10.1016/j.clinthera.2012.09.007

J. C. Orban and C. Ichai, Complications Métaboliques Aigües du Diabète. Réanimation, pp.761-767, 2008.

A. Paisley, R. Yadav, N. Younis, P. Rao-balakrishna, and H. Soran, Dapagliflozin: a review on efficacy, clinical effectiveness and safety, Expert Opinion on Investigational Drugs, vol.11, issue.1, pp.131-140, 2013.
DOI : 10.1001/jama.241.19.2035

H. Rahmoune, P. Thompson, J. Ward, C. Smith, G. Hong et al., Glucose Transporters in Human Renal Proximal Tubular Cells Isolated From the Urine of Patients With Non-Insulin-Dependent Diabetes, Diabetes, vol.54, issue.12, pp.3427-3434, 2005.
DOI : 10.2337/diabetes.54.12.3427

P. Raskin, Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus, Diabetes/Metabolism Research and Reviews, vol.60, issue.5, pp.347-356, 2013.
DOI : 10.1002/dmrr.2403

. Pioglitazone, Sitagliptin Used as Monotherapy in Drug-Naive Patients with Type

S. Sociale, Base des Médicaments et Informations Tarifaires, Assurance Maladie en

M. Shilling and . Raphael, Diabetes, Hyperglycemia, and Infections, Best Practice & Research Clinical Anaesthesiology, vol.22, issue.3, pp.519-535, 2008.
DOI : 10.1016/j.bpa.2008.06.005

J. Tang and T. Kern, Inflammation in Diabetic Retinopathy Progress in Retinal and Eye Research, pp.343-358, 2011.

F. Vidal and . Médicaments, Base de données des prescripteurs en ligne, 2016.

J. L. Waton, Allergie à l'Insuline : Mise au Point!. Revue Française d'Allergologie, pp.336-342, 2011.

J. Wilding, V. Woo, N. Soler, A. Pahor, J. Sugg et al., Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin, Annals of Internal Medicine, vol.156, issue.6, pp.405-415, 2012.
DOI : 10.7326/0003-4819-156-6-201203200-00003

R. Winslow and . Monstre-de-gila, Smug Mug, 2007.

C. Wysham, L. Macconell, D. Maggs, M. Zhou, P. Griffin et al., Five-Year Efficacy and Safety Data of Exenatide Once Weekly, Mayo Clinic Proceedings, vol.90, issue.3
DOI : 10.1016/j.mayocp.2015.01.008

M. Yu, J. Xie, L. Fernandez-lando, S. Kabul, and R. Swindle, Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation, Clinical Therapeutics, vol.38, issue.1, pp.149-160, 2016.
DOI : 10.1016/j.clinthera.2015.11.017

M. Zeadin, C. Petlura, and G. Werstuck, Molecular Mechanisms Linking Diabetes to the Accelerated Development of??Atherosclerosis, Canadian Journal of Diabetes, vol.37, issue.5, pp.345-380, 2013.
DOI : 10.1016/j.jcjd.2013.06.001